Control of malaria and other vector-borne protozoan diseases in the tropics: Enduring challenges despite considerable progress and achievements

Infectious Diseases of Poverty

Volumn 3, Issue 1, 2014, Pages

  Zofou, Denis ^a   Nyasa, Raymond B ^a   Nsagha, Dickson S ^a   Ntie Kang, Fidele ^a,b   Meriki, Henry D ^a   Assob, Jules Clement N ^a   Kuete, Victor ^c  

^a UNIVERSITY OF BUEA   (Cameroon)

^b UNIVERSITY OF DOUALA   (Cameroon)

^c UNIVERSITY OF DSCHANG   (Cameroon)

Author keywords

African trypanosomiasis; Chagas disease; Chemotherapy; Leishmaniasis; Malaria; Vaccine development; Vector control; Vector borne protozoan diseases

Indexed keywords

ALLOPURINOL; AMODIAQUINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ARTEMETHER; ARTEMISININ; ATOVAQUONE; BENFLUMETOL; BENZNIDAZOLE; CHLOROQUINE; CLINDAMYCIN; DOXYCYCLINE; EFLORNITHINE; HALOFANTRINE; INSECTICIDE; KETOCONAZOLE; LINCOMYCIN; MALARIA VACCINE; MEFLOQUINE; MELARSOPROL; MILTEFOSINE; NIFURTIMOX; PENTAMIDINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; SURAMIN; TETRACYCLINE;

AFRICAN TRYPANOSOMIASIS; ANOPHELES; ARTICLE; BED NET; CHAGAS DISEASE; CHEMOPROPHYLAXIS; DRUG DESIGN; FUNDING; GOVERNMENT; HUMAN; HYGIENE; IMMUNE RESPONSE; IMMUNIZATION; INDOOR RESIDUAL SPRAYING; LEISHMANIASIS; MALARIA; NONHUMAN; PARASITE TRANSMISSION; PRIORITY JOURNAL; VECTOR CONTROL;

EID: 84906666696     PISSN: None     EISSN: 20499957     Source Type: Journal    
DOI: 10.1186/2049-9957-3-1     Document Type: Article

References (92)

1. Roll Back Malaria Partnership (RBM) Eliminating Malaria: Learning From the Past, Looking Ahead. 2011 Geneva: Progress &Impact Series Number 8. Press, Roll Back Malaria Partnership (RBM).
2. WHO World Malaria Report 2012 2012, Geneva: WHO Press, WHO.
3. TDR Disease Reference Group on Chagas Disease Human African Trypanosomiasis and Leishmaniasis: Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis. WHO Technical Report Series 2012, 975 100. Geneva: WHO Press, TDR Disease Reference Group on Chagas Disease.
4. Vázquez-Chagoyán JC, Gupta S, Garg NJ. Vaccine development against trypanosoma cruzi and chagas disease. Adv Parasitol 2011, 75:121-46.
5. Gillies MT, Coetzee M. A supplement to the Anophelinae of Africa south of the Sahara (Afrotropical Region). Publ S Afr Inst Med Res 1987, 55:1-143.
6. RTI International Integrated Vector Management Programs for Malaria Control: Programmatic Environmental Assessment C5-22. Washington D.C.: Ed. USAID 2007, RTI International.
7. Curtis CF. Should the use of DDT be revived for malaria vector control?. BioMedica 2002, 22(4):455-461.
8. Lengeler C. Insecticide-treated bednets and curtains for preventing malaria 1. Oxford: Update Software.
9. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, Muga R, Oloo AJ, Steketee RW. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998, 59(5):813-22.
10. Morel CM, Lauer JA, Evans DB. Cost effectiveness analysis strategies to combat malaria in developing countries. BMJ 2005, 331(7528):1299. 10.1136/bmj.38639.702384.AE, 1298848, 16282381.
11. WHO World Malaria Report 2010 2010, 5-32. Geneva: WHO Press, WHO.
12. WHO Global plan for insecticide resistance management in malaria vectors 2012, 2-69. Geneva: WHO Press, WHO.
13. Marshall JM, Taylor CE. Malaria control with transgenic mosquitoes. PLoS Med 2009, 6(2):e1000020.
14. Fang W, Vega-Rodríguez J, Ghosh AK, Jacobs-Lorena M, Kang A, St Leger RJ. Development of transgenic fungi that kill human malaria parasites in mosquitoes. Science 2011, 331(6020):1074-1077. 10.1126/science.1199115, 21350178.
15. Darbro JM, Graham RI, Kay BH, Ryan PA, Thomas MB. Evaluation of entomopathogenic fungi as potential biological control agents of the dengue mosquito, Aedes aegypti (Diptera: Culicidae). Biocontrol Sci Tech 2011, 21(9):1027-1047.
16. WHO Handbook for Integrated Vector Management 2012, 68. Geneva: WHO Press, 978 92 4 150280 1, WHO.
17. Beier JB, Keating J, Githure JI, Macdonald MB, Impoinvil DE, Novak RJ. Integrated vector management for malaria control. Malaria J 2008, 7(Suppl 1):S4.
18. Caldas De Castro M, Yamagata Y, Mtasiwa D, Tanner M, Utzinger J, Keiser J, Singer BH. Integrated urban malaria control: a case study in Dar es Salaam, Tanzania. Am J Trop Med Hyg 2004, 71:103-117.
19. Gilroy AB, Bruce-Chwatt LJ. Mosquito-control by swamp drainage in the coastal belt of Nigeria. Ann Trop Med Parasitol 1945, 39:19-40.
20. Keiser J, Singer BH, Utzinger J. Reducing the burden of malaria in different eco-epidemiological settings with environmental management: a systematic review. Lancet Infect Dis 2005, 5:695-708. 10.1016/S1473-3099(05)70268-1, 16253887.
21. Sharma VP, Sharma RC. Cost effectiveness of the bio-environmental control of malaria in Kheda district, Gujarat. Indian J Malariol 1986, 23:141-145.
22. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev 2009, 22(1):13-36. 10.1128/CMR.00025-08, 2620631, 19136431.
23. Clyde DF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975, 24:397-401.
24. Hoffman SL. Progress towards development of the PfSPZ vaccine for use as tool for eliminating Plasmodium falciparum malaria 2013, S35-p81. Durban South Africa: Abstract Book of the 6th Pan-African MIM Malaria Conference, ICC.
25. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garçon N, Krzych U, Marchand M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation Group. N England J Med 1997, 336:86-91.
26. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy PE. Malaria: progress, perils, and prospects for eradication. J Clin Investigation 2008, 118(4):1266-1276.
27. PATH Staying the Course? Malaria Research and Development in a Time of Economic Uncertainty 2011, Seattle: PATH, ISBN 978-0-9829522-0-7, PATH.
28. The PATH-M Malaria Vaccine Initiative (MVI)-GSK RTS, S malaria vaccine candidate 2012, Fact sheet, November 2012. Available on http://www.malariavaccine.org/files/MVI-GSK-PhaseIIIfactsheetFINAL-web.pdf, The PATH-M Malaria Vaccine Initiative (MVI)-GSK.
29. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, et al. RTS, S clinical trials partnership: first results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875.
30. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, et al. RTS, S Clinical Trials Partnership A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367:2284-2295. RTS, S Clinical Trials Partnership.
31. Mercereau-Puijalon O, Fandeur T, Guilotte M, Bonnefoy S. Parasite features impeding malaria immunity, antigenic diversity, antigenic variation and poor immunogenicity. Res Immunol 1999, 142:690-697.
32. Carvalho LJ, Naniel-Ribeiro M, Goto H. Malaria vaccine: candidate antigens, mechanisms, constraints and prospects. Scandinavian J Immunol 2002, 56:327-348.
33. Mwangoka G, Ogutu B, Msambichaka B, Mzee T, Salim N, Kafuruki S, Mpina M, Shekalaghe S, Tanner M, Abdulla S. Experience and challenges from clinical trials with malaria vaccines in Africa. Malaria J 2013, 12:86.
34. Quijano-Hernandez I, Dumonteil E. Advances and challenges toward a vaccine against Chagas disease. Hum Vaccin 2011, 11:1184-1191.
35. Cornelissen AW, Bakkeren GA, Barry JD, Michels PA, Borst P. Characteristics of trypanosome variant antigen genes active in the tsetse fly. Nucleic Acids Res 1985, 1985(13):4661-4676.
36. Field MC, Lumb JH, Adung'a VO, Jones NG, Engstler M. Macromolecular trafficking and immune evasion in African trypanosomes. Int Rev Cell Mol Biol 2009, 278:1-67.
37. Mkunza F, Olaho WM, Powell CN. Partial protection against natural trypanosomiasis after vaccination with a flagellar pocket antigen from Trypanosoma brucei rhodesiense. Vaccine 1995, 13:151-154. 10.1016/0264-410X(95)93128-V, 7625108.
38. Radwanska M, Magez S, Dumont N, Pays A, Nolan D, Pays E. Antibodies raised against the flagellar pocket fraction of Trypanosoma brucei preferentially recognize HSP60 in cDNA expression library. Parasite Immunol 2000, 22:639-650. 10.1046/j.1365-3024.2000.00348.x, 11123756.
39. Lubega GW, Byarugaba DK, Prichard RK. Immunization with a tubulin-rich preparation from Trypanosoma brucei confers broad protection against African trypanosomosis. Exp Parasitol 2002, 102:9-22. 10.1016/S0014-4894(02)00140-6, 12615162.
40. Stijlemans B, Baral TN, Guilliams M, Brys L, Korf J, Drennan M, Van Den Abbeele J, De Baetselier P, Magez S. A glycosylphosphatidylinositol-based treatment alleviates trypanosomiasis-associated immunopathology. J Immunol 2007, 179:4003-4014.
41. Authié E, Boulangé A, Muteti D, Lalmanach G, Gauthier F, Musoke AJ. Immunisation of cattle with cysteine proteinases of Trypanosoma congolense: targetting the disease rather than the parasite. Int J Parasitol 2001, 31:1429-33. 10.1016/S0020-7519(01)00266-1, 11595229.
42. Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol 1995, 89:83-88.
43. Serebryakov VA, Karakhodznaeva SKH, Dzhumaev MD. Effect of leishmanial vaccinations on the dynamics of immunity to diphteria in conditions of secondary revaccination with adsorbed pertussis-diphteria-tetanus vaccine. Med Parasit Mosk 1972, 41:303-309.
44. Peters NC, Kimblin N, Secundino N, Kamhawi S, Lawyer P, Sacks DL. Vector transmission of leishmania abrogates vaccine-induced protective immunity. PLoS Pathog 2009, 5:e1000484. 10.1371/journal.ppat.1000484, 2691580, 19543375.
45. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002, 420:502-507. 10.1038/nature01152, 12466842.
46. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, Sacks DL. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001, 194:1497-506. 10.1084/jem.194.10.1497, 2193677, 11714756.
47. Selvapandiyan A, Duncan R, Debrabant A, Lee N, Sreenivas G, Salotra P, Nakhasi HL. Genetically modified live attenuated parasites as vaccines for leishmaniasis. Indian J Med Res 2006, 123:455-466.
48. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci 1995, 92:10267-10271. 10.1073/pnas.92.22.10267, 40777, 7479765.
49. Alexander J, Coombs GH, Mottram JC. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998, 161:6794-801.
50. Saravia NG, Escorcia B, Osorio Y, Valderrama L, Brooks D, Arteaga L, Coombs G, Mottram J, Travi BL. Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models. Vaccine 2006, 24:4247-4259. 10.1016/j.vaccine.2005.05.045, 16216395.
51. Uzonna JE, Spath GF, Beverley SM, Scott P. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 2004, 172:3793-3797.
52. Späth GF, Lye LF, Segawa H, Turco SJ, Beverley SM. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect Immun 2004, 72:3622-3627. 10.1128/IAI.72.6.3622-3627.2004, 415719, 15155672.
53. Silvestre R, Cordeiro-Da-Silva A, Santarém N, Vergnes B, Sereno D, Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. J Immunol 2007, 179:3161-3170.
54. Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 2005, 73:6372-6382. 10.1128/IAI.73.10.6372-6382.2005, 1230936, 16177308.
55. Russo DM, Burns JM, Carvalho EM, Armitage RJ, Grabstein KH, Button LL, McMaster WR, Reed SG. Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol 1991, 1991(147):3575-3580.
56. Kedzierski L, Montgomery J, Bullen D, Curtis J, Gardiner E, Jimenez-Ruiz A, Handman E. A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3. J Immunol 2004, 172:4902-4906.
57. Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 1995, 63:4261-4267. 173605, 7591056.
58. Sjölander A, Baldwin TM, Curtis JM, Bengtsson KL, Handman E. Vaccination with recombinant parasite surface antigen 2 from leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 1998, 16:2077-2084. 10.1016/S0264-410X(98)00075-9, 9796067.
59. Launois P, Maillard I, Pingel S, Swihart KG, Xénarios I, Acha-Orbea H, Diggelmann H, Locksley RM, MacDonald HR, Louis JA. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997, 6:541-549. 10.1016/S1074-7613(00)80342-8, 9175832.
60. Julia V, Rassoulzadegan M, Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996, 274:421-423. 10.1126/science.274.5286.421, 8832890.
61. Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 2001, 69:4719-25. 10.1128/IAI.69.8.4719-4725.2001, 98557, 11447143.
62. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005, 21:244-249. 10.1016/j.pt.2005.03.006, 15837614.
63. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, Webb JR, Campos-Neto A, Reed SG. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002, 20:3292-303. 10.1016/S0264-410X(02)00302-X, 12213399.
64. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun 2007, 75:4648-4654. 10.1128/IAI.00394-07, 1951162, 17606603.
65. WHO Guidelines for the treatment of malaria 2010, 211. Geneva: WHO Press, 2, WHO.
66. Mayer DC, Bruce M, Kochurova O, Stewart JK, Zhou Q. Antimalarial activity of a cis-terpenone. Malaria J 2009, 8:139.
67. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. Artemisinin resistance in plasmodium falciparum malaria. The New England J Med 2009, 36:1455-467.
68. Schiltzer M. Antimalarial drugs - what is in use and what is in the pipeline. Arch Pharm Chem Life Sci 2008, 341:149-163.
69. WHO Global report on antimalarial efficacy and drug resistance: 2000-2010 2010, 6-86. Geneva: WHO Press, WHO.
70. Bloland PB. Drug resistance in malaria, WHO/CDS/CSR/DRS 2001, 12-23. Geneva: WHO Press.
71. Thaithong S. Clones of different sensitivities in drug resistant isolates of Plasmodium falciparum. Bull World Health Organ 1983, 61:23-26. 2536066, 6601541.
72. WHO The Quality of Antimalarials. A Study in Selected African Countries 2003, 1-54. Geneva: WHO Press, WHO.
73. Taylor RB, Shakoor O, Behrens RH, Everard M, Low AS, Wangboonskul J, Reid RG, Kolawole JA. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 2001, 357:1933-1936. 10.1016/S0140-6736(00)05065-0, 11425415.
74. WHO Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa 2011, 115. Geneva: WHO Press, WHO.
75. Nwaka S, Ridley RG. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov 2005, 2:919-928.
76. Murray H, Berman J, Davies C, Saravia N. Advances in leishmaniasis. Lancet 2005, 366:1561-1577. 10.1016/S0140-6736(05)67629-5, 16257344.
77. Sawadogo WR, Le Douaron G, Maciuk A, Bories C, Loiseau PM, Figadère B, Guissou IP, Nacoulma OG. In vitro antileishmanial and antitrypanosomal activities of five medicinal plants from Burkina Faso. Parasitol Res 2012, 2012(110):1779-1783.
78. Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 2006, 5:941-955. 10.1038/nrd2144, 17080030.
79. Drug for Neglected Diseases Initiative (DNDi) Visceral Leishmaniasis (VL), DNDi NewsLetter. 2009, Available at http://www.dndi.org/newsletters/n18/4_1.php, Drug for Neglected Diseases Initiative (DNDi).
80. Ryu HJ, Song R, Kim HW, Kim JH, Lee EY, Lee YJ, Song YW, Lee EB. Clinical risk factors for adverse events in allopurinol users. J. Clin. Pharmacol. 2013, 53(2):211-216. 10.1177/0091270012439715, 23436266.
81. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann. Pharmacother. 1993, 27(3):337-343.
82. Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 2005, 14(11):1337-1346. 10.1517/13543784.14.11.1337, 16255674.
83. Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM. Miltefosine in the treatment of cutaneous leishmaniasis caused by leishmania braziliensis in brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010, 4(12):e912. doi:10.1371/journal.pntd.0000912, 10.1371/journal.pntd.0000912, 3006132, 21200420.
84. Kamanzi Atindehou K, Schmid C, Brun R, Koné MW, Traore D. Antitrypanosomal and antiplasmodial activity of medicinal plants from Côte d'Ivoire. J. Ethnopharmacol. 2004, 90(2-3):221-227.
85. Kagira JM, Maina N. Occurrence of multiple drug resistance in Trypanosoma brucei rhodesiense isolated from sleeping sickness patients. Onderstepoort J Veterinary Res 2007, 74:17-22.
86. ClinicalTrials.gov: Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole (CHAGASAZOL). available at: http://clinicaltrials.gov/ct2/show/NCT01162967?term=posaconazole,+Chagas+disease&rank=1; visited on 06/01/2014.
87. ClinicalTrials.gov: a study of the use of oral Posaconazole (POS) in the treatment of asymptomatic Chronic Chagas Disease (P05267 AM1) (STOP CHAGAS). available at http://clinicaltrials.gov/show/NCT01377480; visited on 06/01/2014.
88. ClinicalTrials.gov: proof-of-Concept study of E1224 to treat adult patients with Chagas Disease. available at: http://clinicaltrials.gov/ct2/show/NCT01489228?term=ravuconazole+%28E1224%29&rank=1; visited on 06/01/2014.
89. Program for Appropriate Technology in Health (PATH) Staying the Course? Malaria Research and Development in a Time of Economic Uncertainty 2011, Seattle: PATH, Program for Appropriate Technology in Health (PATH).
90. Roll Back Malaria Partnership (RBM) Malaria funding and resource utilization: the first decade of Roll Back Malaria 2010, 48. Geneva: Progress & Impact Series, Number 1, Roll Back Malaria Partnership (RBM).
91. Pigott D, Atun R, Hay S, Gething PW. Funding for malaria control 2006-2010: a comprehensive global assessment. Malaria J 2012, 11:246. 10.1186/1475-2875-11-246.
92. Global Fund of Innovation for Neglected Diseases (G-FINDER) Neglected Disease Research and Development: A Five Year Review 2012, 30-51. Sydney: Policy Cures, Global Fund of Innovation for Neglected Diseases (G-FINDER).